Cytomegalovirus infection and Guillain-Barre syndrome: The clinical, electrophysiologic, and prognostic features

Neurology

Volumn 47, Issue 3, 1996, Pages 668-673

  Visser, L H ^a   Van Der Meche F G A ^a   Meulstee, J ^a   Rothbarth, P Ph ^a   Jacobs, B C ^a   Schmitz, P I M ^a   Van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; ARTICLE; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CRANIAL NERVE PARALYSIS; CYTOMEGALOVIRUS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ELECTRODIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SERODIAGNOSIS;

EID: 0029817985     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.668     Document Type: Article

References (24)

1. Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3: 565-566.
2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(Suppl):S21-S24.
3. van der Meché FGA, van Doorn PA. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995;37(Suppl 1):S14-S31.
4. Thomas PK. The Guillain-Barré syndrome: no longer a simple concept. J Neurol 1992;239:361-362.
5. van der Meché FGA, Meulstee J, Vermeulen M, Kievit A. Patterns of conduction failure in the Guillain-Barré syndrome. Brain 1988;111:405-416.
6. Hartung HP, Pollard J, Harvey G, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part 1. Muscle Nerve 1995;18:137-153.
7. Feasby TE. Axonal Guillain-Barré. Muscle Nerve 1994;17: 678-679.
8. Yuki N. Pathogenesis of axonal Guillain-Barré syndrome: hypothesis. Muscle Nerve 1994;17:680-682.
9. Honavar M, Tharakan KJ, Hughes RAC, Leibowitz S, Winer JB. A clinicopathological study of the Guillain-Barré syndrome. Brain 1991;114:1245-1269.
10. Hartung HP, Pollard J, Harvey G, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part 2. Muscle Nerve 1995;18:154-164.
11. Winer JB, Hughes RAC, Anderson MJ, Dones JM, Kangro H, Watkins RPF. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-618.
12. van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
13. Visser LH, van der Meché FGA, van Doom PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995;118:841-847.
14. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
15. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981;9(suppl):44-55.
16. Oomes PG, van der Meché FGA, Kleyweg RP, and the Dutch Guillain-Barré Study Group. Liver function disturbances in Guillain-Barré syndrome: a prospective, longitudinal study in 100 patients. Neurology 1996;46:96-100.
17. Kleyweg RP, van der Meché FGA. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
18. Herbrink P, van den Munckhof HAM, Bumkens M, Lindeman J, van Dijk WC. Human serum antibody response in Campylobacter jejuni enteritis as measured by enzyme-linked immunosorbent assay. Eur J Clin Microbiol Infect Dis 1988;7:388-393.
19. Herbrink P, van Loon AM, Rotmans JP, van Knapen F, van Dijk WC. Interlaboratory evaluation of indirect enzyme-linked immunosorbent assay, antibody capture enzyme-linked immunosorbent assay, and immunoblotting for detection of immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 1987;25:100-105.
20. Jacobs BC, Endtz HPh, van der Meché FGA, Hazenberg M, Achtereekte HAM, van Doom PA. Serum anti-GQ1b antibodies recognize epitopes on Campylobacter jejuni from patients with Miller-Fisher syndrome. Ann Neurol 1995;27:260-264.
21. Meulstee J, van der Meché FGA, and the Dutch Guillain-Barré Study Group. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1995;59:482-486.
22. Sobue G, Senda Y, Matsuoka Y, Sobue I. Sensory ataxia: a residual disability of Guillain-Barré syndrome. Arch Neurol 1983;40:86-89.
23. van der Meché FGA, Meulstee J, Kleyweg RP. Axonal damage in Guillain-Barré syndrome. Muscle Nerve 1991;14:997-1002.
24. Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35: 749-752.